Autosomal Hemophilia A, Classic Hemophilia, Factor 8 Deficiency, Congenital, Factor VIII Deficiency, Congenital, Hemophilia A, Congenital
Conditions
Brief summary
This study aims to observe the safety and efficacy of the Xyntha Solofuse prefilled syringe in the setting of routine practice. The primary objective is to detect medically significant events (factor VIII inhibitor). The secondary objective is to observe the overall efficacy and safety of the Xyntha Solofuse prefilled syringe including serious adverse events. In this open-label, non-comparative, observational, non-interventional, retrospective and multi-center study, post-marketing surveillance data will be collected retrospectively for up to 6 months from the initial administration day of the Xyntha Solofuse prefilled syringe injected into patients who have been administered the Xyntha Solofuse prefilled syringe. As specified in the product approval issued by the Ministry of Food and Drug Safety, the study will be conducted for 4 years from the approval date. At least 600 study subjects will be enrolled in this study to meet the MFDS requirements. Although 600 is the assigned number of study subjects, the number of cases will be adjusted considering the actual number of enrolled subjects after the study start day.
Interventions
None listed
Sponsors
Pfizer
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
-. Inclusion criteria To be eligible to enroll in this study, the study subjects will have to meet all the following inclusion criteria: 1. Hemophilia A (congenital factor VIII deficiency) patients who have been administered according to the indication of the product 1) Control and prevention of bleeding episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency) 2) This drug does not contain von Willebrand factor and, therefore, is not indicated in von Willebrand's disease 2. Those who have been administered the Xyntha Solofuse prefilled syringe at least once -
Exclusion criteria
Patients who satisfy the following criteria are not included in the study according to the local labeling: 1. Patients who have a history of hypersensitivity to the Xyntha Solofuse prefilled syringe or the ingredients of this drug. 2. Patients who have a history of hypersensitivity to hamster proteins. 3. Patients who have bleeding disorders other than hemophilia A. 4. Patients who have a history of FVIII inhibitors, or currently have or are suspected of having FVIII inhibitors. In case inhibitor titers quantified in Bethesda Units in the laboratory test results are within the normal laboratory range or at least 0.6 BU/mL. If laboratory tests cannot be performed, the investigator will determine whether or not inhibitors exist based on the clinical assessment results that show a decrease in efficacy of the replacement of FVIII (e.g. bleeding at least once, if the replacement of anti-bleeding agents is needed to be administered, and if frequency or dosage of replacement FVIII therapy needs to be increased). 5. Use of immunomodulatory therapy. (e.g. intravenous injection of immunoglobulin, use of regular systemic corticosteroids, cyclosporine, and mediators of anti-TNF-α)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | From the first administration of Xyntha up to 6 months | An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment Emergent Adverse Event (TEAE) was adverse event that started or worsened in severity after first administration of Xyntha Solofuse up to 6 months. AEs included both serious and non-serious adverse event. |
| Number of Participants With Adverse Events (AEs) by Severity | From the first administration of Xyntha up to 6 months | An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function, and was determined based on investigator's discretion. |
| Number of Participants Who Discontinued Due to Adverse Events | From the first administration of Xyntha up to 6 months | An AE was any untoward medical occurrence in participants who received study drug without regard to possibility of causal relationship. |
| Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events | From the first administration of Xyntha up to 6 months | Treatment-related AE was any untoward medical occurrence attributed to Xyntha in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to treatment was assessed by investigator. AEs included both serious and non-serious AEs. |
| Number of Participants Who Died Due to Adverse Events | From the first administration of Xyntha up to 6 months | An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship. |
| Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery | From the first administration of Xyntha up to 6 months | On-demand treatment according to surgery: treatment to increase factor in preparation for surgery. Overall responses to all injection of Xyntha Solofuse prefilled syringe used to treat bleeding in on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to surgery was assessed on 4 point scale of 1=excellent, 2=good, 3=moderate and 4=no response, higher score = better response. Excellent= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with no additional infusion, good= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with 1 additional infusion, moderate= Probable/slight improvement starting after 8 hours following infusion, with \>=1 additional infusion administered for complete resolution of bleeding episode and no response= No improvement at all between infusions/during 24 hour interval following an infusion/condition worsens |
| Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding | From the first administration of Xyntha up to 6 months | On-demand treatment according to bleeding: treatment administered for spontaneous bleeding/abrasion; not requiring surgery. Overall responses to all injection of Xyntha used to treat bleeding in on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to bleeding was assessed on 4 point scale of 1=excellent, 2=good, 3=moderate,4=no response, higher score=better response. Excellent= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with no additional infusion, good= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with 1 additional infusion, moderate= Probable/slight improvement after 8 hours following infusion, with \>=1 additional infusion administered for complete resolution of bleeding episode and no response= No improvement at all between infusions/during 24 hour interval following an infusion, or condition worsens. |
| Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Surgery | Within 24 hours of on-demand treatment (anytime within the observation period of 6 months) | LETE for on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment. |
| Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Bleeding | Within 24 hours of on-demand treatment (anytime within the observation period of up to 6 months) | LETE for on-demand treatment ((administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment. |
| Number of Infusions Required to Treat Each New Bleeding Episode | From the first administration of Xyntha up to 6 months | It was calculated as total number of injections given throughout the study divided by total number of bleeding events. |
| Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Surgery | From the first administration of Xyntha up to 6 months | The average dose of Xyntha per bleeding event according to surgery in on-demand treatment was calculated as total dose of Xyntha (in IU) throughout the study divided by total number of bleeding event. On-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to surgery means treatment to increase factor in preparation for surgery. |
| Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Bleeding | From the first administration of Xyntha up to 6 months | The average dose of Xyntha per bleeding event was calculated as total dose of Xyntha throughout the study (in International Units \[IU\]) divided by total number of bleeding incidence. On-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to bleeding means treatment administered due to spontaneous bleeding or abrasion. |
| Percentage of Participants With Bleeding Event | From the first administration of Xyntha up to 6 months | — |
| Annualized Bleeding Rates (ABRs) | Within 48 hours after the prophylactic administration of Xyntha (within the duration of 6 months) | Annualized bleeding rate defined as number of bleeds under prophylactic setting (defined as bleeding occurred after 48 hours of prophylactic therapy \[administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding\]) divided by (/) \[(number of prophylactic therapy participants)\*0.5)\] |
| Number of Participants With Less Than Expected Therapeutic Effect (LETE): Prophylactic Therapy | From the first administration of Xyntha up to 6 months | Less than expected therapeutic effect for prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleeding occurred within 48 hours of prophylaxis infusion (defined as: administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding). |
| Average Dose of Infusions Per Bleeding Event: Prophylactic Therapy | From the first administration of Xyntha up to 6 months | The average dose of Xyntha per bleeding event according to prophylaxis therapy treatment was calculated as total dose of Xyntha (in IU) throughout the study divided by total number of bleeding event. Prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleeding occurred within 48 hours of prophylaxis infusion (defined as administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding). |
| Total Factor VIII Consumption | 6 months | Total factor VIII consumption for each participant was calculated by sum of the total amount of Xyntha Solofuse (in IU) infused for each Xyntha Solofuse infusion. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Xyntha Participants who were prescribed with Xyntha Solofuse prefilled syringe, as part of routine treatment, were observed in this study for up to 6 months from the initial administration of Xyntha Solofuse. | 105 |
| Total | 105 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Enrolled, but not received Xyntha | 1 |
Baseline characteristics
| Characteristic | Xyntha | — |
|---|---|---|
| Age, Customized 30- 39 years | 29 Participants | — |
| Age, Customized < 30 years | 19 Participants | — |
| Age, Customized 40- 49 years | 39 Participants | — |
| Age, Customized 50- 59 years | 11 Participants | — |
| Age, Customized >= 60 years | 7 Participants | — |
| Concomitant therapy No | 103 Participants | — |
| Concomitant therapy Yes | 2 Participants | — |
| Concomitant treatments No | 69 Participants | — |
| Concomitant treatments Yes | 36 Participants | — |
| Disease severity Mild | 13 Participants | — |
| Disease severity Moderate | 8 Participants | — |
| Disease severity Severe | 80 Participants | — |
| Disease severity Unknown | 4 Participants | — |
| Duration of the disease, Continuous | 32.4 Years STANDARD_DEVIATION 16.9 | — |
| Family history of allergic reactions to factor VIII products No | 105 Participants | — |
| Family history of allergic reactions to factor VIII products Yes | 0 Participants | — |
| Family history of factor VIII inhibitors No | 105 Participants | — |
| Family history of factor VIII inhibitors Yes | 0 Participants | — |
| Family history of hemophilia A No | 82 Participants | — |
| Family history of hemophilia A Yes | 23 Participants | — |
| Genetic mutation of factor VIII No | 36 Participants | — |
| Genetic mutation of factor VIII Unknown | 69 Participants | — |
| Genetic mutation of factor VIII Yes | 0 Participants | — |
| Hepatic Disorder No | 88 Participants | — |
| Hepatic Disorder Yes | 17 Participants | — |
| Medical history No | 60 Participants | — |
| Medical history Yes | 45 Participants | — |
| Personal history of allergic reactions to factor VIII products No | 105 Participants | — |
| Personal history of allergic reactions to factor VIII products Yes | 0 Participants | — |
| Personal History of Allergic Reactions to Factor VIII Products (within 12 months) No | 103 Participants | — |
| Personal History of Allergic Reactions to Factor VIII Products (within 12 months) Yes | 2 Participants | — |
| Previous exposure to plasma-derived factor VIII No | 34 Participants | — |
| Previous exposure to plasma-derived factor VIII Unknown | 20 Participants | — |
| Previous exposure to plasma-derived factor VIII Yes | 51 Participants | — |
| Previous used factor VIII therapy No | 12 Participants | — |
| Previous used factor VIII therapy Yes | 93 Participants | — |
| Race and Ethnicity Not Collected | — | — Participants |
| Renal Disorder No | 103 Participants | — |
| Renal Disorder Yes | 2 Participants | — |
| Sex: Female, Male Female | 0 Participants | — |
| Sex: Female, Male Male | 105 Participants | — |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 22 / 105 |
| other Total, other adverse events | 15 / 105 |
| serious Total, serious adverse events | 0 / 105 |
Outcome results
Primary
Annualized Bleeding Rates (ABRs)
Annualized bleeding rate defined as number of bleeds under prophylactic setting (defined as bleeding occurred after 48 hours of prophylactic therapy \[administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding\]) divided by (/) \[(number of prophylactic therapy participants)\*0.5)\]
Time frame: Within 48 hours after the prophylactic administration of Xyntha (within the duration of 6 months)
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Xyntha | Annualized Bleeding Rates (ABRs) | 13.33 bleeds per participant |
Primary
Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Bleeding
The average dose of Xyntha per bleeding event was calculated as total dose of Xyntha throughout the study (in International Units \[IU\]) divided by total number of bleeding incidence. On-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to bleeding means treatment administered due to spontaneous bleeding or abrasion.
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Xyntha | Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Bleeding | 2140.08 IU/event | Standard Deviation 640.32 |
Primary
Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Surgery
The average dose of Xyntha per bleeding event according to surgery in on-demand treatment was calculated as total dose of Xyntha (in IU) throughout the study divided by total number of bleeding event. On-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to surgery means treatment to increase factor in preparation for surgery.
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Xyntha | Average Dose of Infusions Per Bleeding Event: On-Demand Treatment According to Surgery | 2619.29 IU/event | Standard Deviation 1089.07 |
Primary
Average Dose of Infusions Per Bleeding Event: Prophylactic Therapy
The average dose of Xyntha per bleeding event according to prophylaxis therapy treatment was calculated as total dose of Xyntha (in IU) throughout the study divided by total number of bleeding event. Prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleeding occurred within 48 hours of prophylaxis infusion (defined as administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding).
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Xyntha | Average Dose of Infusions Per Bleeding Event: Prophylactic Therapy | 1881.33 IU/event | Standard Deviation 531.88 |
Primary
Number of Infusions Required to Treat Each New Bleeding Episode
It was calculated as total number of injections given throughout the study divided by total number of bleeding events.
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Xyntha | Number of Infusions Required to Treat Each New Bleeding Episode | 1.22 Infusions | Standard Deviation 0.57 |
Primary
Number of Participants Who Died Due to Adverse Events
An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship.
Time frame: From the first administration of Xyntha up to 6 months
Population: The safety population included all participants who received at least one dose of Xyntha Solofuse prefilled syringe.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Xyntha | Number of Participants Who Died Due to Adverse Events | 0 Participants |
Primary
Number of Participants Who Discontinued Due to Adverse Events
An AE was any untoward medical occurrence in participants who received study drug without regard to possibility of causal relationship.
Time frame: From the first administration of Xyntha up to 6 months
Population: The safety population included all participants who received at least one dose of Xyntha Solofuse prefilled syringe.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Xyntha | Number of Participants Who Discontinued Due to Adverse Events | 0 Participants |
Primary
Number of Participants With Adverse Events (AEs) by Severity
An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs were classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function, and was determined based on investigator's discretion.
Time frame: From the first administration of Xyntha up to 6 months
Population: The safety population included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xyntha | Number of Participants With Adverse Events (AEs) by Severity | Mild | 10 Participants |
| Xyntha | Number of Participants With Adverse Events (AEs) by Severity | Moderate | 5 Participants |
| Xyntha | Number of Participants With Adverse Events (AEs) by Severity | Severe | 0 Participants |
Primary
Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Bleeding
LETE for on-demand treatment ((administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment.
Time frame: Within 24 hours of on-demand treatment (anytime within the observation period of up to 6 months)
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Xyntha | Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Bleeding | 0 Participants |
Primary
Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Surgery
LETE for on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) was defined as no response rated after each infusion of 2 consecutive infusions within 24 hours after on-demand treatment.
Time frame: Within 24 hours of on-demand treatment (anytime within the observation period of 6 months)
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Xyntha | Number of Participants With Less Than Expected Therapeutic Effect (LETE): On-Demand Treatment According to Surgery | 0 Participants |
Primary
Number of Participants With Less Than Expected Therapeutic Effect (LETE): Prophylactic Therapy
Less than expected therapeutic effect for prophylaxis therapy defined as breakthrough (spontaneous/non-traumatic) bleeding occurred within 48 hours of prophylaxis infusion (defined as: administration of Xyntha not for the treatment of a bleed but for the prevention of bleeding).
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Xyntha | Number of Participants With Less Than Expected Therapeutic Effect (LETE): Prophylactic Therapy | 6 Participants |
Primary
Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding
On-demand treatment according to bleeding: treatment administered for spontaneous bleeding/abrasion; not requiring surgery. Overall responses to all injection of Xyntha used to treat bleeding in on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to bleeding was assessed on 4 point scale of 1=excellent, 2=good, 3=moderate,4=no response, higher score=better response. Excellent= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with no additional infusion, good= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with 1 additional infusion, moderate= Probable/slight improvement after 8 hours following infusion, with \>=1 additional infusion administered for complete resolution of bleeding episode and no response= No improvement at all between infusions/during 24 hour interval following an infusion, or condition worsens.
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding | Excellent | 28 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding | Good | 3 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding | Moderate | 0 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Bleeding | No response | 0 Participants |
Primary
Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery
On-demand treatment according to surgery: treatment to increase factor in preparation for surgery. Overall responses to all injection of Xyntha Solofuse prefilled syringe used to treat bleeding in on-demand treatment (administration of an unscheduled dose of Xyntha Solofuse prefilled syringe to stop bleeding) according to surgery was assessed on 4 point scale of 1=excellent, 2=good, 3=moderate and 4=no response, higher score = better response. Excellent= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with no additional infusion, good= Definite pain relief and/or improvement in signs of bleeding within 8 hours after an infusion, with 1 additional infusion, moderate= Probable/slight improvement starting after 8 hours following infusion, with \>=1 additional infusion administered for complete resolution of bleeding episode and no response= No improvement at all between infusions/during 24 hour interval following an infusion/condition worsens
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery | Excellent | 6 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery | Good | 0 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery | Moderate | 0 Participants |
| Xyntha | Number of Participants With Overall Responses on a 4-Point Scale to the Injections Used to Treat Bleeding: On-Demand Treatment According to Surgery | No response | 0 Participants |
Primary
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in participants who received Xyntha without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment Emergent Adverse Event (TEAE) was adverse event that started or worsened in severity after first administration of Xyntha Solofuse up to 6 months. AEs included both serious and non-serious adverse event.
Time frame: From the first administration of Xyntha up to 6 months
Population: The safety population included all participants who received at least one dose of Xyntha Solofuse prefilled syringe.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xyntha | Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | AEs | 15 Participants |
| Xyntha | Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) | SAEs | 0 Participants |
Primary
Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events
Treatment-related AE was any untoward medical occurrence attributed to Xyntha in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Relatedness to treatment was assessed by investigator. AEs included both serious and non-serious AEs.
Time frame: From the first administration of Xyntha up to 6 months
Population: The safety population included all participants who received at least one dose of Xyntha Solofuse prefilled syringe.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Xyntha | Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events | AEs | 2 Participants |
| Xyntha | Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events | SAEs | 0 Participants |
Primary
Percentage of Participants With Bleeding Event
Time frame: From the first administration of Xyntha up to 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Xyntha | Percentage of Participants With Bleeding Event | 6.67 percentage of participants |
Primary
Total Factor VIII Consumption
Total factor VIII consumption for each participant was calculated by sum of the total amount of Xyntha Solofuse (in IU) infused for each Xyntha Solofuse infusion.
Time frame: 6 months
Population: The efficacy analysis set included all participants who received at least one dose of Xyntha Solofuse prefilled syringe. Here, Overall Number of Participants Analyzed signifies those participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Xyntha | Total Factor VIII Consumption | 106116.16 IU | Standard Deviation 55747.74 |